Dose selection and go/no-go decisions in a second indication by leveraging published clinical trial data for drugs/classes approved in multiple indications
PC6 - Pharmacometrics Phisticuffs 3* – Is Biostatistics a more important partner for drug development than Pharmacometrics, or are they equal partners?
1:30 PM - 2:00 PM MDT
Pharmacometrics Phisticuffs 3* – Is Biostatistics a more important partner for drug development than Pharmacometrics, or are they equal partners?
Model-informed drug development with hyper accelerated time to submission - exemplified with depemokimab regulatory submissions in interleukin-5-driven diseases"